• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com


Paper Details

COMPARATIVE EVALUATION OF THE EFFICACY, SAFETY AND QUALITY OF LIFE WITH THE TREATMENT OF ROSUVASTATIN AND ATORVASTATIN IN DYSLIPIDEMIA PATIENTS

*S.Alavudeen, Madhavan Mallayasamy, P.Rajasoundarapandian, R.Meera

Journal Title:World Journal of Pharmaceutical Research
Abstract


Background and Aim :Lipid lowering drugs provide benefit in patients across the entire spectrum of cholesterol levels; primarily by reducing levels of low-density lipoprotein cholesterol .This study is to assess the percentage reduction in lipid levels achieved in Rosuvastatin and Atorvastatin in dyslipidemic patients and also to define patient groups who are at high risk for dyslipidemia and analyse the percentage of adverse effect in Rosuvastatin and Atorvastatin. Materials and Methods: This study enrolled 60 patients and divided into four groups of 15 patients in each group. Group-1 patients received Rosuvastatin 10 mg tablet once in a day, Group-2 received Atorvastatin 20 mg tablet once in a day, Group-3 patients received Rosuvastatin 20 mg tablet once in a day, and Group-4 received Atorvastatin 40 mg tablet once in a day for a period of 20 weeks.Results :Statistical analysis using student unpaired t-test shows that Rosuvastatin 10mg is better than Atorvastatin 20mg and also shows that Rosuvastatin 20mg is better than Atorvastatin 40mg in the reduction of total cholesterol,Low density lipoprotein, Triglycerides and in increasing of HDL and found to be statistically significant.The comparison of Diastolic and systolic Blood Pressure in rosuvastatin and atorvastatin patients did not show any significant difference. The Side effects differed between the rosuvastatin and atorvastatin groups; the incidence of Side effects in rosuvastatin and atorvastatin patients is not statistically significant. Conclusion : Patients treated with rosuvastatin had significantly greater reductions in LDL cholesterol, total cholesterol, triglycerides levels compared with those receiving atorvastatin. Patients receiving rosuvastatin were more likely to attain lipid goals compared with patients treated with atorvastatin.

Download